Figure 1
Figure 2A
Figure 2B
Figure 3
Acute toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| Grade 0 | 23 (60.5%) | 36 (50%) | 59 (53.6%) |
| Grade 1 | 8 (21.1%) | 28 (38.9%) | 36 (32.7%) |
| Grade 2 | 6 (15.8%) | 7 (9.7%) | 13 (11.8%) |
| Grade X | 1 (2.6%) | 1 (1.4%) | 2 (1.9%) |
| Grade 1−2 | 14 (36.8%) | 35 (48.6%) | 49 (44.5%) |
Late toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| Grade 0 | 22 (57.9%) | 43 (59.7%) | 65 (59.1%) |
| Grade 1 | 12 (31.6%) | 24 (33.3%) | 36 (32.7%) |
| Grade 2 | 3 (7.9%) | 3 (4.2%) | 6 (5.5%) |
| Grade X | 1 (2.6%) | 2 (2.8%) | 3 (2.7%) |
| Grade 1−2 | 15 (39.5%) | 27 (37.5%) | 42(38.2%) |
Description of the population
| Variables | All cohort (n = 110) | Group 1 (n = 38) | Group 2 (n = 72) | p-value |
|---|---|---|---|---|
| Age (years) Median (range) | 67 (43−85) | 67 (48−80) | 67 (43−85) | p = 0.51 |
| Clinical stage | ||||
| cT1a N0 | 2 (1.8%) | 1 (2.6%) | 1 (1.4%) | |
| cT1b N0 | 47 (42.8%) | 20 (52.6%) | 27 (37.5%) | |
| cT1c N0 | 59 (53.6%) | 17 (44.8%) | 42 (58.3%) | p = 0.42 |
| cT1b N1 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| cT2 N0 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Histological type | ||||
| Ductal carcinoma in situ (DCIS) | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| Invasive ductal carcinoma | 70 (63.6%) | 26 (68.4%) | 44 (61.1%) | p = 0.46 |
| Invasive lobular carcinoma | 19 (17.3%) | 5 (13.2%) | 14 (19.45%) | |
| Others | 20 (18.2%) | 6 (15.8%) | 14 (19.45%) | |
| Multifocal disease | 6 (5.4%) | 4 (10.5%) | 2 (2.8%) | p = 0.21 |
| Pathological Stage pT | ||||
| pTis | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| pT1a | 3 (2.7%) | 0 (0.0%) | 3 (4.2%) | |
| pT1b | 41 (37.3%) | 16 (42.1%) | 25 (34.7%) | p=0.40 |
| pT1c | 59 (53.6%) | 20 (52.6%) | 39 (54.2%) | |
| pT2 | 6 (5.5%) | 1 (2.6%) | 5 (6.9%) | |
| Pathological Stage pN | ||||
| pN0 | 88 (80.0%) | 32 (84.2%) | 56 (77.8%) | |
| pN1mi | 7 (6.4%) | 3 (7.9%) | 4 (5.6%) | p=0.71 |
| pN1a | 14 (12.7%) | 3 (7.9%) | 11 (15.3%) | |
| pN3 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Grading | ||||
| G1 | 15 (13.7%) | 7(18.4%) | 8 (11.1%) | |
| G2 | 68 (61.8%) | 24 (63.2%) | 44 (61.1%) | p = 0.67 |
| G3 | 21 (19.1%) | 6 (15.8%) | 15 (20.8%) | |
| Gx | 6 (5.4%) | 1 (2.6%) | 5 (7%) | |
| Adjuvant therapy Calculated on 109 patients | ||||
| None | 2 (1.8%) | 0 (0.0%) | 2 (2.8%) | |
| Chemotherapy | 6 (5.5%) | 2 (5.4%) | 4 (5.6%) | p = 0.92 |
| Endocrine therapy | 85 (78%) | 29 (78.4%) | 56 (77.7%) | |
| Chemotherapy + Endocrine therapy | 12 (11%) | 4 (10.8%) | 8 (11.1%) | |
| Chemotherapy + Trastuzumab | 4 (3.7%) | 2 (5.4%) | 2 (2.8%) |